Triggerable RNA nanodevices

Justin Halman\textsuperscript{1}, Emily Satterwhite\textsuperscript{1}, Jaclyn Smollett\textsuperscript{1}, Eckart Bindewald\textsuperscript{3}, Lorena Parlea\textsuperscript{2}, Mathias Viard\textsuperscript{2,3}, Paul Zakrevsky\textsuperscript{2}, Wojciech K. Kasprzak\textsuperscript{3}, Kirill A. Afonin\textsuperscript{1}, Bruce A. Shapiro\textsuperscript{2}

\textsuperscript{1}Department of Chemistry, University of North Carolina at Charlotte, 9201 University City Boulevard, Charlotte 28223, North Carolina, USA
\textsuperscript{2}Gene Regulation Chromosome Biology Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick 21702, Maryland, USA
\textsuperscript{3}Basic Science Program, Leidos Biomedical Research, Inc., Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick 21702, Maryland, USA

Abstract

The targeted and conditional activation of pharmaceuticals is an increasingly important feature in modern personalized medicine. Nucleic acid nanoparticles show tremendous potential in this exploit due to their programmability and biocompatibility. Among the most powerful nucleic acid specific treatments is RNA interference-based therapeutics. RNA interference is a naturally occurring phenomenon in which specific genes are effectively silenced. Recently we have developed two different strategies based on customized multivalent nucleic acid nanoparticles with the ability to conditionally activate RNA interference in diseased cells as well as elicit detectable fluorescent responses.\cite{1,2} These novel technologies can be further utilized for the simultaneous delivery and conditional intracellular activation of multiple therapeutic and biosensing functions to combat various diseases.

Nucleic acid nanoparticles have become increasingly attractive in therapeutic research due to their high customizability and various functionalities while retaining biocompatibility and ease in production.\cite{3–10} Specifically, RNA has garnered attention through research exploiting its plethora of functionalities in sensing and treating various diseases. RNA interference (RNAi) which is the effective termination of specific protein production, serves as an important aspect of RNA therapeutics.\cite{11–13} RNAi occurs naturally through various pathways but can be taken advantage of synthetically using a number of designed RNA strands (i.e., short-interfering RNA, or siRNA, and slightly elongated dicer-substrate RNA or DS RNA).\cite{14} The ability to simultaneously deliver and activate multiple functionalities (including but not limited to RNAi) would prove immensely beneficial to personalized medicine. Additionally, predicting the structure, folding, and tertiary interactions of RNA would greatly benefit and accelerate the design of therapeutics.
We introduced nucleic acid-based programmable system with the ability to conditionally activate multiple functionalities via introduction of split cognate strands\(^{[15-16]}\). Each strand contributes half of a designed DS RNA duplex, which upon re-association and further dicing forms a functional therapeutic. The initially prepared non-functional DNA-RNA hybrids contain either ssDNA or, as in the highlighted work\(^{[2]}\), ssRNA over-hangs of different lengths, called toeholds (Figure 1A). These toeholds allow for the non-functional cognate hybrids to interact and, through branch migration, form more energetically suitable complexes – that is the formation of DS RNA. To allow for multiple functionalities to be delivered and activated simultaneously, previously designed RNA rings\(^{[17]}\) were used in this work as scaffolds carrying six hybrids. The efficacy of re-association based on varying toehold length was assessed using both native-PAGE and FRET. Toeholds of 2, 4, 6, and 8 nucleotides were investigated for their efficiency of re-association. FRET analyses revealed that longer toeholds led to improved re-association rates. The functionality of these particles was confirmed in different human cell lines.

The previously mentioned functionality operates using DNA-RNA hybrids. An additional scheme has also been exploited using RNA-RNA interactions (Figure 1B).\(^{[1]}\) In this system an RNA strand is designed to interact with specific mRNA strands in cells. The designed RNA strand contains both “therapeutic” and “trigger” components; these two components are designed to dissociate from each other in the presence of a “trigger” mRNA and form both a byproduct as well as a short hairpin-like RNA which can be processed by dicer to form functional siRNA. The conformational change takes place due to the presence of an extended ssRNA toehold in the “trigger”-binding strand which allows for the specific binding to an mRNA present in diseased cells. This novel approach allows for the conditional activation of therapeutic RNAs only where a designated trigger strand is present. For potential use in treatment of diseases, such as cancer, this can be a tremendous boon as it will reduce off target silencing and allow for more precise treatment. Rational design of these RNA nanoparticles was performed using HyperFold, a novel multistrand nucleic acid modeling approach used for predicting structures and interactions between nucleic acid strands as well as the formation of pseudoknots (RNA structures with non-nested base pairing). This \textit{in silico} approach supplemented \textit{in vitro} experiments to confirm RNA structures and interactions.

The conditionally activated RNA nanoparticles, published back-to-back in Nano Letters \([1, 2]\), offer alternative techniques supplementing each other. The combination of these technologies provides the ability to deliver multiple functionalities simultaneously. Currently there are two synthesis techniques for constructing these architectures and their functional moieties: transcription of individual components followed by a one pot assembly, as is the case for the switch, or co-transcriptional assembly, as in the case of the hybrid nanostructures. The former consists of transcribing DNA strands separately, then purifying and recombining in equimolar concentration by heating (causing denaturation) and snap-cooling to achieve the designed conformation. The latter is a more simplistic approach as it can be done in one step and offers great promise for an alternative pathway to functionalization of particles \textit{in vivo}. 

\textit{RNA Dis. Author manuscript; available in PMC 2021 July 23.}
There are other approaches of designed RNA constructs that can switch between different conformations. For example, riboregulators have been developed, that enable protein translation conditional to the binding of a trigger RNA \(^{[18]}\). In a bacterial system, designed riboswitches that are responsive to temperature and binding of a ligand were recently shown to be able to regulate both transcriptional and translational efficiency \(^{[19]}\). Such approaches are not necessarily in competition, but instead have different uses. The two aforementioned approaches are well suited for designing reporter genes or gene circuits but require the de novo design of genomic regions upstream of the translation start site of a gene. The conditional activation of RNA interference (the focus of this research highlight) on the other hand, is based on comparatively short synthetic noncoding RNAs that function in the context of human cancer cells and are thus closer to traditional small molecule therapeutics. Not only will it be interesting to compare these different novel tools for the “smart” control of gene expression: exciting opportunities abound to combine such approaches, leading to systems that allow ever more complex control of the cellular machinery by operating on different levels simultaneously.

Overall, published techniques can be used in conjunction with pre-existing nucleic acid nanostructures thus increasing the control over the formulation and co-delivery of pharmaceuticals and biosensors for the treatment and detection of a large variety of diseases.

Acknowledgements

This work has been funded in whole or in part with Federal funds from the Frederick National Laboratory for Cancer Research, National Institutes of Health, under Contract No. HHSN261200800001E. This research was supported in part by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The research was supported by UNC Charlotte start-up funds to K.A.A.

References

1. Bindewald E, Afonin KA, Viard M, Zakrevsky P, Kim T, Shapiro, BA. Multistrand Structure Prediction of Nucleic Acid Assemblies and Design of RNA Switches. Nano letters 2016; 16:1726–1735. [PubMed: 26926528]
2. Afonin KA, Viard M, Tedbury P, Bindewald E, Parlea L, Howington M, et al. The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities. Nano letters 2016; 16:1746–1753. [PubMed: 26926382]
3. Afonin KA, Grabow WW, Walker FM, Bindewald E, Dobrovolskaia MA, Shapiro BA, et al. Design and self-assembly of siRNA-functionalized RNA nanoparticles for use in automated nanomedicine. Nat Protoc 2011; 6:2022–2034. [PubMed: 22134126]
4. Afonin KA, Kasprzak WK, Bindewald E, Kireeva M, Viard M, Kashlev M, et al. In silico design and enzymatic synthesis of functional RNA nanoparticles. Acc Chem Res 2014; 47:1731–1741. [PubMed: 24758371]
5. Afonin KA, Viard M, Koyfman AY, Martins AN, Kasprzak WK, Panigaj M, et al. Multifunctional RNA nanoparticles. Nano letters 2014; 14:5662–5671. [PubMed: 25267559]
6. Rychahou P, Haque F, Shu Y, Zaytseva Y, Weiss HL, Lee EY, et al. Delivery of RNA nanoparticles into colorectal cancer metastases following systemic administration. ACS Nano 2015; 9:1108–1116. [PubMed: 25652125]
7. Li H, Lee T, Dziubla T, Pi F, Guo S, Xu J, et al. RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications. Nano today 2015; 10:631–655. [PubMed: 26770259]
8. Shu Y, Pi F, Sharma A, Rajabi M, Haque F, Shu D, et al. Stable RNA nanoparticles as potential new generation drugs for cancer therapy. Adv Drug Deliv Rev 2014; 66:74–89. [PubMed: 24270010]
9. Khisamutdinov EF, Jasinski DL, Guo P. RNA as a boiling-resistant anionic polymer material to build robust structures with defined shape and stoichiometry. ACS Nano 2014; 8:4771–4781. [PubMed: 24694194]
10. Guo P. The emerging field of RNA nanotechnology. Nature nanotechnology 2010; 5:833–842.
11. Fire A, Xu S, Montgomery MK, Costas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806–811. [PubMed: 9486653]
12. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15:188–200. [PubMed: 11157775]
13. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. Embo J 2001; 20:6877–6888. [PubMed: 11726523]
14. Rose SD, Kim DH, Amarzguioui M, Heidel JD, Collingwood MA, Davis M, et al. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic acids research 2005; 33:4140–4156. [PubMed: 16049023]
15. Afonin KA, Desai R, Viard M, Kireeva ML, Bindewald E, Case CL, et al. Co-transcriptional production of RNA-DNA hybrids for simultaneous release of multiple split functionalities. Nucleic acids research 2014; 42:2085–2097. [PubMed: 24194608]
16. Afonin KA, Viard M, Martins AN, Locket SJ, Maciag AE, Freed EO, et al. Activation of different split functionalities on re-association of RNA-DNA hybrids. Nature nanotechnology 2013; 8:296–304.
17. Grabow WW, Zakrevsky P, Afonin KA, Chworos A, Shapiro BA, Jaeger L. Self-assembling RNA nanorings based on RNAI/II inverse kissing complexes. Nano letters 2011; 11:878–887. [PubMed: 21229999]
18. Green AA, Silver PA, Collins JJ, Yin P. Toehold switches: de-novo-designed regulators of gene expression. Cell 2014; 159:925–939. [PubMed: 25417166]
19. Rossmanith J, Narberhaus F. Exploring the modular nature of riboswitches and RNA thermometers. Nucleic acids research 2016. 44:5410–23 [PubMed: 27060146]
Figure 1. Schematic representation of two alternative ways, described in highlighted papers, to conditionally activate various functionalities intracellularly. A: corresponds to the hybrid approach and B: corresponds to the two stranded switch approach.